4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The evolutionary old forebrain as site of action to develop new psychotropic drugs

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          Previously, the authors have developed a model of how reward-seeking and distress- avoiding behaviour is regulated by the human brain. The forebrain’s evolution in vertebrates was taken as a starting point.

          Aims:

          The authors want to inspire colleagues to study in particular the pharmacological effects on the described ancient forebrain structures in order to modify specific symptoms of mental disorders.

          Methods:

          Compilation of data and ideas of previous articles, with examples to illustrate.

          Results:

          A primary (lamprey-like), secondary (frog-like) and tertiary (mammal-like) forebrain can be distinguished, organized according to a Russian doll model. The first constituent is primarily involved in producing the emotional response, while the last is principally concerned with constructing conscious cognitive behaviour (including verbal and written communication). Mental disorders comprise (partly related and partly unrelated) biological and rational phenomena. The secondary system regulates the intensity of reward-seeking and distress-avoiding behaviour. An essential component of the primary forebrain evaluates the results of behavioural actions: the lateral habenula-projecting pallidum. These neurons regulate the activity of ascending dopaminergic pathways. The authors suggest that these habenula-projecting pallidum neurons are targeted by subanaesthetic dosages of ketamine. The medial habenula is enriched with nicotinergic acetylcholine receptors and regulates the activity of ascending adrenergic and serotonergic neurons. This may link varenicline-induced hostility to selective serotonin reuptake inhibitor-induced aggression.

          Conclusions:

          Studying the effects of new compounds on the primary and secondary brains in lampreys and frogs may yield interesting new treatments of mental disorders.

          Related collections

          Most cited references76

          • Record: found
          • Abstract: not found
          • Article: not found

          Parallel organization of functionally segregated circuits linking basal ganglia and cortex.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Antidepressant effects of ketamine in depressed patients.

            A growing body of preclinical research suggests that brain glutamate systems may be involved in the pathophysiology of major depression and the mechanism of action of antidepressants. This is the first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression. Seven subjects with major depression completed 2 test days that involved intravenous treatment with ketamine hydrochloride (.5 mg/kg) or saline solutions under randomized, double-blind conditions. Subjects with depression evidenced significant improvement in depressive symptoms within 72 hours after ketamine but not placebo infusion (i.e., mean 25-item Hamilton Depression Rating Scale scores decreased by 14 +/- SD 10 points vs. 0 +/- 12 points, respectively during active and sham treatment). These results suggest a potential role for NMDA receptor-modulating drugs in the treatment of depression.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ketamine blocks bursting in the lateral habenula to rapidly relieve depression

              The N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine has attracted enormous interest in mental health research owing to its rapid antidepressant actions, but its mechanism of action has remained elusive. Here we show that blockade of NMDAR-dependent bursting activity in the 'anti-reward center', the lateral habenula (LHb), mediates the rapid antidepressant actions of ketamine in rat and mouse models of depression. LHb neurons show a significant increase in burst activity and theta-band synchronization in depressive-like animals, which is reversed by ketamine. Burst-evoking photostimulation of LHb drives behavioural despair and anhedonia. Pharmacology and modelling experiments reveal that LHb bursting requires both NMDARs and low-voltage-sensitive T-type calcium channels (T-VSCCs). Furthermore, local blockade of NMDAR or T-VSCCs in the LHb is sufficient to induce rapid antidepressant effects. Our results suggest a simple model whereby ketamine quickly elevates mood by blocking NMDAR-dependent bursting activity of LHb neurons to disinhibit downstream monoaminergic reward centres, and provide a framework for developing new rapid-acting antidepressants.
                Bookmark

                Author and article information

                Journal
                J Psychopharmacol
                J. Psychopharmacol. (Oxford)
                JOP
                spjop
                Journal of Psychopharmacology (Oxford, England)
                SAGE Publications (Sage UK: London, England )
                0269-8811
                1461-7285
                26 September 2018
                December 2018
                : 32
                : 12
                : 1277-1285
                Affiliations
                [1 ]University of Groningen, Groningen Research Institute of Pharmacy (GRIP), Unit of PharmacoTherapy, -Epidemiology & -Economics, Groningen, The Netherlands
                [2 ]Mental Health Institute Westelijk Noord-Brabant (GGZWNB), Halsteren, The Netherlands
                [3 ]Mental Health Research Institute, Tomsk National Research Medical Centre of the Russian Academy of Sciences, Tomsk, Russian Federation
                [4 ]National Research Tomsk Polytechnic University, School of Non-Destructive Testing & Security, Division for Control and Diagnostics, Tomsk, Russian Federation
                Author notes
                [*]Anton JM Loonen, University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, -Epidemiology & -Economics, Antonius Deusinglaan 1, 9713AV Groningen, The Netherlands. Email: a.j.m.loonen@ 123456rug.nl
                Author information
                https://orcid.org/0000-0003-4942-6195
                Article
                10.1177_0269881118798617
                10.1177/0269881118798617
                6247451
                30255719
                73f74fed-b70c-4e87-902e-6ce1e1010e85
                © The Author(s) 2018

                This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ( http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ( https://us.sagepub.com/en-us/nam/open-access-at-sage).

                History
                Categories
                Review

                Pharmacology & Pharmaceutical medicine
                amygdala,habenula,gph,ketamine,varenicline
                Pharmacology & Pharmaceutical medicine
                amygdala, habenula, gph, ketamine, varenicline

                Comments

                Comment on this article